Wockhardt Ltd. News, Corporate filings and Earnings/Conference Calls

Keep track of all breaking news and updates on Wockhardt Ltd. from all sources in a single place.

Load latest

Wockhardt Ltd.

29 May 2025

1730.80

2.58%

Result

Wockhardt Ltd - 532300 - Outcome Of The Board Meeting

BSE India

Pursuant to SEBI Listing Regulations, 2015, Please find enclosed herewith the Outcome of the Board Meeting held today i.e. 29th May, 2025, along with the Audited Standalone and Consolidated financial results for the quarter and year ended 31st March, 2025.

pdf

	Mar 2025	Dec 2024	Mar 2024	Change QoQ%	Change YoY%
Total Revenue Qtr	758.00	729.00	754.00	4.0%	0.5%
Operating Profit Qtr	64.00	128.00	-103.00	-50.0%	162.1%
Net Profit Qtr	-25.00	14.00	-169.00	-278.6%	85.2%
Earning Per Share Adjusted latest Qtr	-1.54	0.86	-10.40	-279.1%	85.2%

* Consolidated data

Detailed Results

Wockhardt Ltd.

23 May 2025

1730.80

2.58%

Board Meeting

Wockhardt Ltd - 532300 - Board Meeting Intimation for Pursuant To Regulation 29(1) (A) And (D) …

BSE India

Wockhardt Ltdhas informed BSE that the meeting of the Board of Directors of the Company is scheduled on 29/05/2025 ,inter alia, to consider and approve (1)The Audited Financial Results (Standalone & Consolidated) of the Company for the quarter and financial year ended 31st March, 2025; & 2) Raising of funds as mentioned in the attached intimation.

pdf

Wockhardt Ltd.

22 May 2025

1730.80

2.58%

Company Update

Wockhardt Ltd - 532300 - Compliances-Reg.24(A)-Annual Secretarial Compliance

BSE India

Pursuant to Regulation 24A of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015; we enclose herewith the Annual Secretarial Compliance Report for the financial year ended 31st March, 2025.

pdf

Wockhardt Ltd.

14 May 2025

1730.80

2.58%

Company Update

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Monitoring Agency Report

BSE India

Pursuant to Regulation 32(6) of SEBI ( Listing Obligations & Disclosure Requirements) Regulations 2015, read with regulation 173 A of the SEBI (Issue of Capital & Disclosure Requirements) Regulations 2018, please find enclosed Monitoring Agency Reports towards utilisations of proceeds of the Qualified Institutions Placement ("QIPs") for the quarter ended 31st March, 2025 issued by CRISIL Ratings Limited duly reviewed and taken on record by the Board of Directors and Audit Committee of the Company.

pdf

Wockhardt Ltd.

12 Apr 2025

1730.80

2.58%

US tariffs, if extended to Indian pharma industry, will be a challenge: Wockhardt's Huzaifa Khorakiwala

Business Line

Confident that its product, WCK-5222-ZENIC, which has given 97% success in phase-3 clinical trials, would save millions of lives annually

Number of FII/FPI investors increased from 152 to 171 in Mar 2025 qtr.

Wockhardt Ltd.

11 Apr 2025

1730.80

2.58%

Company Update

Wockhardt Ltd - 532300 - Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018

BSE India

Pursuant to Regulation 74(5) of SEBI ( Depositories and Participants ) Regulations , please find enclosed the Compliance Certificate received from MUFG Intime India Private Limited, Registrar and Transfer Agent of the Company for the quarter ended 31st March, 2025.

pdf

Wockhardt Ltd.

08 Apr 2025

1730.80

2.58%

Company Update

Wockhardt Ltd - 532300 - Intimation For Incorporation Of A Step-Down Subsidiary Company

BSE India

Pursuant to Regulation 30 read with Schedule III of the Securities and Exchange Board of India (Listing Obligations and Disclosure Requirements) Regulations, 2015, we hereby inform you that Wockhardt Bio AG, a subsidiary of the Company, has incorporated a new Wholly Owned Subsidiary in Ireland by the name Wockhardt Antibiotics (Ireland) Limited. Consequent to the Incorporation, Wockhardt Antibiotics (Ireland) Limited has become a Step- Down Subsidiary of the Company.

pdf

Wockhardt Ltd.

08 Apr 2025

1730.80

2.58%

Wockhardt Not To Face Significant Impact Of US Tariffs, Says Chairman Khorakiwala

NDTV Profit

Wockhardt's exposure to the US market is just 5%, with plans to exit the generic business soon.

Wockhardt Ltd. is trading above all available SMAs

Wockhardt to exit residual US generics business for commercial reasons

Business Line | 07 Apr 2025 1 more

Wockhardt Ltd.

01 Apr 2025

1730.80

2.58%

Company Update

Wockhardt Ltd - 532300 - Announcement under Regulation 30 (LODR)-Press Release / Media Release

BSE India

Pursuant to Regulation 30 of SEBI Listing Regulations, please find enclosed Press Release - "Paediatric US Cancer Patient with Recalcitrant Blood and Liver Infection Successfully Treated with ZaynichTM (Zidebactam/Cefepime, WCK 5222)

pdf

Wockhardt Ltd.

27 Mar 2025

1730.80

2.58%

SAST

Wockhardt Ltd - 532300 - Closure of Trading Window

BSE India

This is to inform you that pursuant to Company''s ''Code of Conduct for regulating, monitoring, and reporting trading by designated persons'' (''the Code''), the Trading Window for dealing in equity shares of the Company will be closed from 1st April, 2025 until 48 hours after the declaration of audited financial results of the Company for the financial year ended 31st March, 2025.

pdf

Is Wockhardt Ltd. worth buying?

446 Votes:

Buy 73.32%

Sell 17.26%

Hold 9.42%